Cadila Pharma Launches Vasograin EC with FDA-Approved Migraine Formula

The well-known migraine drug Vasograin has a new formulation called Vasograin EC, which was announced by Cadila Pharmaceuticals. The updated formulation is currently manufactured in a US FDA-approved facility that complies with global quality and regulatory standards.

Vasograin EC's smaller tablet size was intended to increase patient adherence and compliance. Targeting both acute and protracted migraine attacks, it is designed to promote quick and long-lasting migraine relief.

“At Cadila Pharmaceuticals, Care continues to improving patient outcomes by ensuring our medications meet the highest regulatory and quality benchmarks.” While sharing the company’s vision behind the launch, a spokesperson from Cadila Pharmaceuticals said.

The business owes Vasograin EC's 42 percent increase over the past two years to its ongoing adoption by patients and medical experts. In the ergotamine market, the brand is now the market leader with an estimated 84% market share.

The company also reported that more than two lakh shops around India have sold more than 400 crore Vasograin tablets. Given the growing need for migraine treatment options, Cadila Pharmaceuticals has pledged to provide formulations that meet international production standards while being accessible in home markets.